JPetroInc
1 week ago
hey swordie I see you changed my opening TOMDF header
lolzzz - hiding the facts will change "nothing" about what took place here ...
for those that truly understand the financial gravity & catastrophe of this twice orchestrated CEO scam
but here's good, accurate, trustworthy & worthwhile FDA medically approved COVID treatment literature
for you and the thread - served up like room service no less - right to the front door:
Why More People Should be Prescribed Paxlovid for COVID | Johns Hopkins | Bloomberg School of Public Health
https://publichealth.jhu.edu/2024/why-more-people-should-be-prescribed-paxlovid-for-covid
John Hopkins Medical Center - can't get much better or argue with them - eh Swordie...?
https://www.centerforhealthsecurity.org/
"One of the best tools for preventing severe complications from COVID infection is the prescription antiviral drug Paxlovid. But not nearly as many people who could benefit from it are being prescribed it, says Amesh Adalja, MD, FIDSA, a senior scholar at the Johns Hopkins Center for Health Security who specializes in infectious diseases and pandemic preparedness. Adalja says that both patients and providers need to be better informed about the benefits of Paxlovid and other antivirals like it.
Paxlovid is extremely effective when taken within five days of symptom onset. In clinical trials, it reduced the risk of hospitalization and death by almost 90% in unvaccinated people. “It’s a tremendous tool that's completely underutilized,” says Adalja.
How does Paxlovid work?
“Paxlovid is a class of antiviral drug called a protease inhibitor,” explains Adalja. It prevents the SARS-CoV-2 virus, which causes COVID-19 infection, from replicating in the body. At a molecular level, “Paxlovid works by disrupting the protein cutting process of SARS-CoV-2,” he explains. “It blocks an essential step in the virus’s life cycle.”
Who is Paxlovid recommended for?
Paxlovid is designed to benefit people at high risk of severe illness who are at least 12 years old and weigh at least 88 pounds. Its purpose is to prevent hospitalization and death, not to decrease symptoms or to help you recover faster, although patients who take it may experience one or both of those benefits.
Who is considered “high risk” for severe COVID-19 illness, hospitalization, or death?
According to the CDC, people are more likely to experience severe COVID-19 illness if they are over 50 years old, unvaccinated or not up to date on COVID-19 vaccination, immunocompromised, or have certain medical conditions.
“Any medical condition such as diabetes, hypertension, heart disease, any lung condition like asthma or COPD, would be considered high risk,” says Adalja. Other common risk factors include being overweight, obese, or pregnant. “The majority of Americans probably have some high risk factor,” he says. “A lot of people would benefit from Paxlovid just based on their weight status.”
Is Paxlovid being prescribed as often as it should be?
“Antiviral prescribing is underutilized in the United States,” Adalja says. “There are many people with high risk conditions who are not being prescribed Paxlovid [or] an alternative antiviral like molnupiravir.”
This may be due to misconceptions, including by physicians, about who should take Paxlovid. “Some might say, ‘we're gonna wait, you don't look that bad,’ which is a complete misunderstanding of how the drug works,” says Adalja. Paxlovid is designed to be given early on to prevent symptoms from becoming more severe. The decision to prescribe someone Paxlovid for a COVID infection should be made based on a patient’s risk factors for severe disease, regardless of symptom severity.
The same problem exists with antivirals for influenza. “Many high-risk people do not get prescribed an influenza antiviral despite evidence that they benefit,” says Adalja. Doctors may be more comfortable prescribing Tamiflu because they’re more familiar with it, but Tamiflu is also underutilized.
How can we improve patient education around Paxlovid?
One reason not enough people know about Paxlovid is that it was under emergency use authorization for quite a while, which prohibited Pfizer from advertising the drug. Instead, they relied on doctors to bring it up. Starting in 2023, Pfizer began promoting Paxlovid to consumers through social media ads and commercials. “People complain about direct-to-patient advertising, but it works,” says Adalja. “When patients know a drug by name, they’re more likely to ask their doctor about it.”
It’s important that patients feel empowered to ask their health care providers about any and all treatment options, he says. “Patients should be asking their doctors, ‘Would I benefit from Paxlovid?’ ‘Would I benefit from Tamiflu?’ ‘Do I really need this antibiotic?’
Are there alternatives to Paxlovid?
Currently there are two other treatments to prevent hospitalization from COVID: Molnupiravir, which is another oral antiviral taken at home, and Remdesivir, which is a three-day daily IV infusion given in a health care facility.
Molnupiravir is a good alternative for individuals taking medications that may interact with Paxlovid, says Adalja.
Are there any downsides to taking Paxlovid if you don’t have a risk factor for severe illness?
“It’s always a risk-benefit ratio,” says Adalja. If you don't have risk factors for severe disease and you take Paxlovid, you may experience the side effects—an altered sense of taste, possible gastrointestinal upset, and possible rebound symptoms—without the benefits the medication is designed to provide.
Can Paxlovid help prevent long COVID?
While some early studies signaled that Paxlovid might reduce a person’s chance of developing long COVID, more recent research indicates that it does not. This includes a study published in January 2024 that found no connection between Paxlovid treatment and long COVID symptoms in vaccinated, non-hospitalized individuals.
There are newer antivirals not yet available in the U.S. that have a stronger signal for preventing long COVID, says Adalja.
Do concerns about COVID rebound* outweigh the benefits of taking Paxlovid?
No. “[Rebound] doesn’t happen to everyone—studies show maybe 1 in 5 people who take Paxlovid experience rebound symptoms,” says Adalja. “But even those who do get rebound—with or without taking Paxlovid— don’t do badly.” For people who take Paxlovid and experience rebound, symptoms are generally mild to moderate and they do not require hospitalization.
“COVID rebound was really made out to be a bigger and more common issue than it is, due to news stories about people like President Biden experiencing it,” he explains. The risk of rebound—whether or not it can be definitively linked to Paxlovid—shouldn't preclude someone who's high risk from taking Paxlovid, and it definitely shouldn’t preclude doctors from prescribing it.
*COVID rebound is the return of symptoms after someone initially recovers from COVID. The order of events generally looks like this: A person is infected with COVID and feels symptomatic; their symptoms subside over the course of the infection; they may even test negative for COVID on a home antigen test; a few days later, their symptoms return, and they may test positive again on a home antigen test.
How much does Paxlovid cost?
Through the end of 2023, Paxlovid was free for Americans, with the costs covered by the federal government. An agreement between Pfizer and the U.S. Department of Health and Human Services will ensure Paxlovid remains free through the end of 2024 for patients who are insured through Medicare and Medicaid or uninsured. It will continue to be free through 2028 for individuals who are uninsured and underinsured. Paxlovid is covered by many private insurance plans (costs vary by plan).
How can I get a prescription for Paxlovid?
If you test positive for COVID, talk to your doctor as soon as possible about any factors that put you at greater risk for severe illness and whether you would benefit from taking Paxlovid.
If you don’t have a health care provider, the nationwide Test to Treat program helps people access low- or no-cost treatments quickly. Anyone who tests positive for COVID (or flu) can also access free telehealth care and treatment through the Home Test to Treat program.
Paxlovid, Remdesivir and Molnupiravir - all FDA approved and legal
...and still being administered to sick COVID patients and saving lives
so much better than that non-EUA Tollovid fake gromwell root Chinese extract crap and its CEO
pocketing almost a kewel $720k/yr. for achieving absolutely nothing ...
but maybe taking on-line courses for his doctorates degree
all the while the pps plummeted while he did nothing to stop the dilution carnage from robbing his SH's
aprox. $1-Mil./yr. in salary, boneses, options, expenses, travel, insurances, retirement, etc
not once but twice backed by the same Astoria, Queens financial mafia no less
and in addition to the CEO shyster - 3.3-Bil.OS toxic death spiral shares were issued
almost in sync with every worthless PR - and there's 200 of them
SMH - its lights permanently out - cause TOMDF's jig is up
Todos Medical Developing Anti-COVID Pill - my royal arse - yet another bold faced lie...!
MOO shill touts and dolts
theswordman
2 weeks ago
BNO News @BNOFeed
Weekly U.S. COVID update:
- New cases: 85,366 est.
- Average: 113,856 (-22K)
- States reporting: 50/50
- In hospital: 10,458 (-1K)
- In ICU: 1,402 (+7)
- New deaths: 1,202
- Average: 1,322 (-112)
BNO ANALYSIS
This is the 29th week in a row with more than 1,000 new COVID deaths, or nearly 48,000 deaths during the same period.
So far this year, more than 2.8 million cases of COVID have been reported in the U.S., causing 243,599 hospitalizations and 24,406 deaths.
theswordman
3 weeks ago
SUN NITE--BNO
BNO News @BNOFeed
Weekly U.S. COVID update:
- New cases: 97,352 est.
- Average: 136,429 (-22K)
- States reporting: 50/50
- In hospital: 11,785 (-1K)
- In ICU: 1,395 (-208)
- New deaths: 1,116
- Average: 1,434 (-114)
BNO ANALYSIS--This is the 28th week in a row with more than 1,000 new COVID deaths, or nearly 47,000 deaths during the same period.
So far this year, nearly 2.8 million cases of COVID have been reported in the U.S., causing 234,000 hospitalizations and 23,204 deaths.
JoeForkeyBolo
4 weeks ago
The question that is never answered is this:
Why provide your company name again on the second investor call, if you claim that caused the error on the first investor call?
A. I forgot about the first call where I was presented as an analyst.
B. They made the mistake AGAIN on the second call. Gerald should have corrected it. It's all his fault.
C. I wanted to be presented as an analyst again. I liked the feeling of importance from the first call.
The facts support answer C. The first call could have been a mistake. The second call definitely was not a mistake. It was intentional because the caller already knew how he would be presented on the call if he provided his company name in lieu of informing the host he was a private investor, as other private investors had done.
Here's an article I found in The Wall Street Journal. Does this sound like someone you've heard on an investor earnings call? On perhaps multiple calls?
https://www.wsj.com/articles/SB120301945499169247
Analyze This: Hoaxer Haunts Earnings Calls
By Betsy McKay
Feb. 16, 2008
Some big companies have had a surprise during their earnings conference calls this quarter -- and it has nothing to do with the weak economy.
At least seven times just the past three weeks, a mystery caller has cleverly insinuated himself into the normally well-manicured ritual of the quarterly calls. As top executives of publicly traded companies respond to securities analysts' questions about their balance sheets, he impersonates a well-known analyst to get called upon. Then, usually declaring himself to be "Joe Herrick of Gutterman Research," he launches into his own version of analyst-speak.
"Congratulations on the solid numbers -- you always seem to come through in challenging times," he said to Leo Kiely, president and chief executive officer of Molson Coors Brewing Co., on Feb. 12, convincingly parroting the obsequious banter common to the calls. "Can you provide some more color as to what you are doing for your supply chain initiatives to reduce manufacturing costs per hectoliter, as you originally promised $150 million in synergy or savings to decrease working capital?"
Analysts say the caller's questions, though credibly phrased, are too off-target for a real analyst. It's more like "consultant-speak," says a disdainful Bryan Spillane, a Banc of America Securities analyst, a victim of one of Mr. Herrick's impersonations. Analysts deal with often-wonky financial details, but "savings per hectoliter" rarely comes up.
But many CEO's have had more trouble telling the difference. Most have gamely tried to answer the questions. Mr. Kiely and two other Molson executives stuck politely with the caller through three detailed follow-ups. Timothy Wolf, the company's global chief financial officer, closed by telling him, "We think we will have some more positive encouraging things to share with you next month in New York," according to a transcript of the call. A Molson spokesman said that to him the caller sounded legitimate at the time.
Executives at PepsiCo Inc., Dean Foods Co., Newell Rubbermaid Inc. and others have had similar experiences since around mid-January. The caller first gives a familiar name to conference-call operators to earn a turn speaking in the calls -- in which dozens of listeners can dial in, but typically just a handful of analysts known to the company get to ask questions. When he's called upon, he corrects the conference-call operator and identifies himself as Joe Herrick (or Harrick in one transcript). He says he is from a firm called Gutterman Research, or in one case Vladimir Research, according to transcripts provided by Thomson Financial.
Analysts and companies contacted about the caller are stymied as to who he could be. Searches using several potential spellings failed to turn up the name or firms on a Financial Industry Regulatory Authority database of registered securities firms and brokers, or on the Securities and Exchange Commission's Investment Adviser Public Disclosure Web site. A Google search found transcripts of several earnings conference calls in which Mr. Herrick has participated. A New York City telephone number used by the caller to phone into one conference call, and obtained by The Wall Street Journal, disconnects immediately when dialed. Of course, Mr. Herrick could still pop up and prove he is for real.
Meanwhile, annoyed executives and analysts are wondering why someone would want to play a game with dry business calls that normally follow a tightly controlled formula -- unless the game is the whole point. They can't figure out how the caller is getting any benefit from so closely mimicking them. "If he was spoofing I would hope he'd be funnier," says Bill Schmitz, an analyst at Deutsche Bank Securities.
Word of the impersonations has been slow to spread. Mr. Schmitz outed the caller on Newell Rubbermaid's Jan. 31 call, having already heard him several times going back to mid-January. Yet the caller was still using other names to get access as late as Thursday, in a call with Jarden Corp. Yesterday, a caller gave a different name and firm, Mindful Capital Investments, on a call with Hormel Foods Corp., but sounded as if he were reading from a similar script. Mr. Herrick's questions are usually narrowly focused on details of a company's results from well-known cost-savings techniques such as "lean management" and Six Sigma, or else supply-chain issues. They're virtually the same on each call, and he often follows up aggressively.
In the Newell Rubbermaid call, Mr. Herrick asked the company's president and chief executive, Mark Ketchum, to outline his "top initiatives regarding lean manufacturing" and Six Sigma. Afterward, Mr. Schmitz came on and warned the executives.
"Hey guys. First, this guy, Joe Gutterman [sic], every conference call this quarter, he logs on as somebody's name and asks these crazy efficiency questions," he said. "So going forward keep in mind you should just disconnect him when he dials in. This is like the sixth call in a row he's done that. It's really annoying." Mr. Schmitz speculates that Mr. Herrick is "some minion" at a consulting firm trying to do clandestine research on companies' use of Six Sigma techniques.
"Our quarterly earnings calls are key opportunities to us to interact with the investment community and to explain our results," says a Newell Rubbermaid spokesman, David Doolittle. "Anyone who would come on the call and use some of that time unproductively is disruptive."
Some companies are now on the alert. Coca-Cola Co. executives listen to the calls of PepsiCo, and they heard Mr. Herrick bombard PepsiCo Chairman and CEO Indra Nooyi on her Feb. 7 call. So Coke gave select analysts a secret password to use to ask questions during its own call Wednesday -- "Diet Coke" -- according to analysts who participated in the call. A Coke spokesman wouldn't comment on steps the company took beyond saying it was "prepared for this and had a contingency plan in place."
Coke's caution was evident when Banc of America's Mr. Spillane, the earlier impersonation victim, posed a detailed question about how much of the company's currency-neutral operating profit growth was organic rather than coming from acquisitions or cost savings. "We hesitated on you for a minute because as we take these questions we are just trying to make sure that in fact you are who you say you are," Coke's chief financial officer, Gary Fayard, said before launching into an answer. "I am the real deal," Mr. Spillane replied.
PepsiCo, not to be outdone by Coke, says it's tightening its screening process to ensure callers are legitimate. "If we find out differently they will be cut off immediately," says a PepsiCo spokesman.
While competition to get into the question queue is keen for a call hosted by PepsiCo or other large corporation, because many analysts and investors dial in, getting to ask a question on a smaller company's call is easy. That makes some of Mr. Herrick's impersonations even stranger, says Bill Pfund, vice president of investor relations for WMS Industries Inc., a slot machine maker in Waukegan, Ill. "It's an open forum," he says. "If you have a question, just come in under your name." It's also unusual for someone to participate in calls for such a broad swath of industries, from beverages to slot machines.
In WMS's conference call Feb. 6, Mr. Herrick asked president and CEO Brian Gamache about "operational improvement initiatives revolving around lean and Six Sigma," according to a transcript. "You always [seem] to come through in a very challenging time," he made sure to say in conference-call style, applauding the company's "good results."
Mr. Herrick's continued appearance on conference calls is becoming a running joke in the analyst community, says John Faucher, a beverage analyst with J.P. Morgan, whose place Mr. Herrick took in the PepsiCo call. Mr. Faucher, who has been keeping tabs on the caller by instant messaging with clients, took a sort of revenge by spoofing Mr. Herrick in a research note following Coke's earnings call on Wednesday. "The only real disappointment on the Coke call was not hearing about their 6 sigma and RONA policies," he wrote.
Mr. Herrick is giving analysts another reason to look forward to a big conference many of them plan to attend in Boca Raton, Fla. next week. Says Mr. Faucher: "One of the big questions is, will Joe Herrick from Gutterman Research show up?"
Register for real-time alerts, custom portfolio, and market movers
redspeed
19 hours ago
LUCKYBUTT
22 hours ago
Hot Features
Premium
